IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1857 
Small font sizeDefault font sizeIncrease font size
Navigate Here
     My Preferences 
     Manuscript submission


This article has been cited by
1A pilot study to identify the longitudinal serum metabolite profiles to predict the development of hyperuricemia in essential hypertension
Heru Zhao,Yin Zhang,Bin Liu,Lulu Zhang,Mei Bao,Li Li,Ning Zhao,Muhummad Hussain,Yuexi Wang,Jianfeng Yi,Peng Chen,Cheng Lu
Clinica Chimica Acta.2020;510()466
2Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association
Suzanne V. Arnold,Deepak L. Bhatt,Gregory W. Barsness,Alexis L. Beatty,Prakash C. Deedwania,Silvio E. Inzucchi,Mikhail Kosiborod,Lawrence A. Leiter,Kasia J. Lipska,Jonathan D. Newman,Francine K. Welty
3Nebivolol suppresses asymmetric dimethylarginine and attenuates cyclosporine-induced nephrotoxicity and endothelial dysfunction in rats
Wafaa A. Hewedy,Dalia K. Mostafa
Pharmacological Reports.2016;68(6)1319
4Nebivolol suppresses asymmetric dimethylarginine and attenuates cyclosporine-induced nephrotoxicity and endothelial dysfunction in rats
Mark D. Mamrack
Pharmacological Reports.2020;68(6)83
5Hypertension treatment: Is there a place for b-adrenoblockers?
L O Minushkina
Systemic Hypertension.2013;10(1)48
6The role of nebivolol in the management of hypertensive patients: from pharmacological profile to treatment guidelines
Claudio Ferri
Future Cardiology.2021;17(8)1421
7Real-world efficacy and safety of nebivolol in Korean patients with hypertension from the BENEFIT KOREA study
Jinho Shin,Yu Jeong Choi,Geu-Ru Hong,Dong Woon Jeon,Dae-Hyeok Kim,Young Youp Koh,Giuseppe Mancia,Athanasios J. Manolis,Hyuck-Jun Yoon,Sang Won Park
Journal of Hypertension.2020;38(3)527
8Therapeutic Properties of Highly Selective -blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease
Waleed AlHabeeb,Sanaa Mrabeti,Ahmed Adel Ibrahim Abdelsalam
Cardiovascular Drugs and Therapy.2022;36(5)959
9Type of -blocker use among patients with versus without diabetes after myocardial infarction
Suzanne V. Arnold,John A. Spertus,Kasia J. Lipska,David E. Lanfear,Fengming Tang,Anna Grodzinsky,Darren K. McGuire,M. Odette Gore,Abhinav Goyal,Thomas M. Maddox,Mikhail Kosiborod
American Heart Journal.2014;168(3)273
Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow